LONDYN, 2 grudnia 2025 r. /PRNewswire/ — Firma LONGi ogłosiła wyniki globalnych testów terenowych wydajności swojej platformy technologicznej Back Contact (BC) oraz modułu Hi-MO9. We współpracy z globalnymi klientami i renomowanymi instytucjami zewnętrznymi firma LONGi zainicjowała program systematycznych globalnych testów terenowych po wprowadzeniu tej technologii na rynek. Dane pokazują, że Hi-MO9 wykazuje stabilność i spójność… Continue reading LONGi publikuje globalne dane terenowe dotyczące technologii BC: wydajność i niezawodność przekraczają oczekiwania
Category: Newswire
LONGi publie des données de terrain sur la technologie BC mondiale : Les performances et la fiabilité dépassent les attentes
LONDRES, 2 décembre 2025 /PRNewswire/ — LONGi a annoncé les résultats de la performance globale sur le terrain de sa plateforme technologique Back Contact (BC) et du module Hi-MO9. En collaboration avec des clients internationaux et des institutions tierces faisant autorité, LONGi a lancé un programme systématique d’essais sur le terrain à l’échelle mondiale après… Continue reading LONGi publie des données de terrain sur la technologie BC mondiale : Les performances et la fiabilité dépassent les attentes
LONGi Releases Global BC Technology Field Data: Performance and Reliability Exceed Expectations
LONDON, Dec. 2, 2025 /PRNewswire/ — LONGi announced the global field performance results of its Back Contact (BC) technology platform and Hi-MO9 module. In collaboration with global customers and authoritative third-party institutions, LONGi initiated a systematic global field-testing program following the technology’s launch. The data demonstrate that the Hi-MO9 exhibits stability and consistency exceeding expectations… Continue reading LONGi Releases Global BC Technology Field Data: Performance and Reliability Exceed Expectations
LONGi veröffentlicht globale BC-Technologie-Felddaten: Leistung und Zuverlässigkeit übertreffen die Erwartungen
LONDON, 2. Dezember 2025 /PRNewswire/ — LONGi hat die weltweiten Feldleistungsergebnisse seiner Back-Contact-Technologieplattform (BC) und seines Hi-MO9-Moduls bekannt gegeben. In Zusammenarbeit mit globalen Kunden und renommierten unabhängigen Institutionen hat LONGi nach der Einführung der Technologie ein systematisches globales Feldtestprogramm initiiert. Die Daten zeigen, dass Hi-MO9 eine Stabilität und Konsistenz aufweist, die die Erwartungen hinsichtlich der tatsächlichen Stromerzeugungsleistung, der wirtschaftlichen Vorteile des Systems und der Umweltverträglichkeit übertrifft. Continue Reading… Continue reading LONGi veröffentlicht globale BC-Technologie-Felddaten: Leistung und Zuverlässigkeit übertreffen die Erwartungen
LONGi publica resultados globales de su tecnología BC: rendimiento y fiabilidad superan las expectativas
MADRID, 2 de diciembre de 2025 /PRNewswire/ — LONGi anunció los resultados globales del rendimiento en campo de su plataforma tecnológica de Contacto Posterior (BC) y el módulo Hi-MO9. En colaboración con clientes globales e instituciones externas de prestigio, LONGi inició un programa sistemático de pruebas de campo globales tras el lanzamiento de la tecnología.… Continue reading LONGi publica resultados globales de su tecnología BC: rendimiento y fiabilidad superan las expectativas
LONGi Releases Global BC Technology Field Data: Performance and Reliability Exceed Expectations
LONDON, Dec. 2, 2025 /PRNewswire/ — LONGi announced the global field performance results of its Back Contact (BC) technology platform and Hi-MO9 module. In collaboration with global customers and authoritative third-party institutions, LONGi initiated a systematic global field-testing program following the technology’s launch. The data demonstrate that the Hi-MO9 exhibits stability and consistency exceeding expectations… Continue reading LONGi Releases Global BC Technology Field Data: Performance and Reliability Exceed Expectations
Cango Inc. Reports Third Quarter 2025 Unaudited Financial Results
DALLAS, Dec. 2, 2025 /PRNewswire/ — On December 1, Cango Inc. (NYSE: CANG) (“Cango” or the “Company”) announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial and Operational Highlights Total revenues were US$224.6 million in the third quarter of 2025, an increase of 60.6% compared with the… Continue reading Cango Inc. Reports Third Quarter 2025 Unaudited Financial Results
Arthur J. Gallagher & Co. Acquires First Actuarial
ROLLING MEADOWS, Ill., Dec. 2, 2025 /PRNewswire/ — Arthur J. Gallagher & Co. today announced the acquisition of UK-based First Actuarial. Terms of the transaction were not disclosed. First Actuarial provides pension administration, employee benefits, consultancy and investment services to employers and pension plan trustees throughout the UK. The First Actuarial team, led by David… Continue reading Arthur J. Gallagher & Co. Acquires First Actuarial
Prezzee Brings AI-Powered Magic to the Holidays with Free Santa and Carolers Experiences
NEW YORK, Dec. 2, 2025 /PRNewswire/ — Prezzee, the global digital gifting platform, is making spirits bright with the return of its AI-powered Magical Moments experiences. Available now, Prezzee Magical Moments offers two free, interactive ways to celebrate the holidays — a personalized video message from Santa Claus and a festive carolers experience that brings laughter,… Continue reading Prezzee Brings AI-Powered Magic to the Holidays with Free Santa and Carolers Experiences
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new… Continue reading Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy